BrainStorm Cell Therapeutics Reports FY 2025 Earnings Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Source: seekingalpha
- Earnings Beat: BrainStorm Cell Therapeutics reported a FY 2025 GAAP EPS of -$1.11, surpassing expectations by $0.50, indicating improvements in financial management despite ongoing losses.
- Cash Position: As of December 31, 2025, the company had approximately $0.3 million in cash, cash equivalents, and restricted cash, highlighting liquidity challenges that necessitate further financing to support operations and R&D.
- Funding Progress: Subsequent to year-end, the company secured an additional $2 million through two private placements, alleviating short-term funding pressures and providing financial backing for future R&D projects, thereby boosting market confidence.
- Strategic Financing: BrainStorm recently secured $1 million in strategic financing, reflecting investor confidence in its business outlook and potentially providing crucial funding support for the company's ongoing development efforts.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
